转化医学

订阅

MedSci主页 / 所有栏目 / 转化医学

Nature：非编码RNA PVT1可能成为癌症治疗新靶点

2014-06-27 佚名 不详

非编码癌症疗法RNAPVT1
关注

2014年6月27日 讯 /生物谷BIOON/ --近日，刊登在国际著名杂志Nature上的一篇研究论文中，来自美国明尼苏达大学等处的研究人员通过研究发现至少和20%的癌症发病相关的一种关键促癌基因也有其致病弱点；MYC是和癌症相关的一种基因，其同伙-一种名为PVT1的非编码RNA，其或许可以帮助科学家们理解MYC向癌细胞提供“燃料”的机制。 研究者Anindya Bagchi表示，我们都知道M

近日，刊登在国际著名杂志Nature上的一篇研究论文中，来自美国明尼苏达大学等处的研究人员通过研究发现至少和20%的癌症发病相关的一种关键促癌基因也有其致病弱点；MYC是和癌症相关的一种基因，其同伙-一种名为PVT1的非编码RNA，其或许可以帮助科学家们理解MYC向癌细胞提供“燃料”的机制。

研究者Anindya Bagchi表示，我们都知道MYC的扩增会引发癌症，但是同时我们也知道MYC并不会单独扩增，其常常会和附近染色体区域的基因一起扩增；因此本文中研究者想知道是否MYC的“邻居”基因在MYC扩增中所扮演的角色。研究者发现MYC和PVT1可以同时进行基因扩增，在细胞中PVT1可以帮助增强MYC蛋白质的危险“活动”。

研究者Bagchi表示，文章中我们主要对名为8q24的基因组区域进行研究，其包含有MYC基因，通常在癌细胞中进行表达，研究者将MYC同附近区域的PVT1进行分离，利用一种染色体工程特殊基因操作技术，研究者开发出了三种不同分离模式的小鼠模型：单独分离MYC；包含PVT1但不包含MYC区域；携带区域基因的配对MYC。

当癌症促进细胞产生更多的MYC时，其同时也可以增加细胞中的PVT1的水平，随后就会增加MYC的含量；研究者表示，PVT1或许是MYC蛋白质的关键调节子，这将可以帮助我们理解为何MYC可以将癌症放大以及其致病机理。

长期以来MYC一直是让科学家们难以捉摸的药物靶点，通过将MYC和PVT1偶联，研究者就可以有效抑制癌症的生长并且限制MYC进入前癌在水平，这就可以使得PVT1作为一种理想的药物靶点来控制主要的癌症基因的表达。

最后研究者Bagchi说道，目前后面有许多问题需要研究清楚，比如如何使得PVT1稳定？或者在细胞中增强MYC的表达，揭示MYC和PVT1之间的分子关联对于开发靶向杀灭癌细胞的新药或疗法提供了新的研究思路和希望。

原始出处

Yuen-Yi Tseng, Branden S. Moriarity, Wuming Gong, Ryutaro Akiyama, Ashutosh Tiwari, Hiroko Kawakami, Peter Ronning, Brian Reuland, Kacey Guenther, Thomas C. Beadnell, Jaclyn Essig, George M. Otto, M. Gerard O’Sullivan, David A. Largaespada, Kathryn L. Schwertfeger, York Marahrens, Yasuhiko Kawakami & Anindya Bagchi.PVT1 dependence in cancer with MYC copy-number increase.Nature 08 April 2014

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2054771, encodeId=39792054e7162, content=<a href='/topic/show?id=c81a14914be' target=_blank style='color:#2F92EE;'>#PVT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14914, encryptionId=c81a14914be, topicName=PVT)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/UdV6ialcayj7Qv8RQm1mVfNYPKxjiaolxwglAZpCo6CwjTicOroW2Xb0Kxnc65viaxGpkuqHW7WzzbYgRLw3qooDoA/132, createdBy=04c22500137, createdName=紫砂壶, createdTime=Wed Aug 20 05:46:00 CST 2014, time=2014-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792917, encodeId=3ae31e9291715, content=<a href='/topic/show?id=270014915b3' target=_blank style='color:#2F92EE;'>#PVT1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14915, encryptionId=270014915b3, topicName=PVT1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Wed Sep 03 02:46:00 CST 2014, time=2014-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844149, encodeId=2ef71844149f9, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Fri Oct 24 12:46:00 CST 2014, time=2014-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880140, encodeId=ef75188014016, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jul 05 10:46:00 CST 2014, time=2014-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743418, encodeId=e03b1e434180f, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Sat Mar 07 21:46:00 CST 2015, time=2015-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288137, encodeId=bee4128813e49, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sun Jun 29 04:46:00 CST 2014, time=2014-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517343, encodeId=a3c5151e3437a, content=<a href='/topic/show?id=817b64646b3' target=_blank style='color:#2F92EE;'>#治疗新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64646, encryptionId=817b64646b3, topicName=治疗新靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=251911073486, createdName=12498f1em11(暂无昵称), createdTime=Sun Jun 29 04:46:00 CST 2014, time=2014-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584622, encodeId=2016158462221, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sun Jun 29 04:46:00 CST 2014, time=2014-06-29, status=1, ipAttribution=)]
    2014-08-20 紫砂壶

    #PVT#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2054771, encodeId=39792054e7162, content=<a href='/topic/show?id=c81a14914be' target=_blank style='color:#2F92EE;'>#PVT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14914, encryptionId=c81a14914be, topicName=PVT)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/UdV6ialcayj7Qv8RQm1mVfNYPKxjiaolxwglAZpCo6CwjTicOroW2Xb0Kxnc65viaxGpkuqHW7WzzbYgRLw3qooDoA/132, createdBy=04c22500137, createdName=紫砂壶, createdTime=Wed Aug 20 05:46:00 CST 2014, time=2014-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792917, encodeId=3ae31e9291715, content=<a href='/topic/show?id=270014915b3' target=_blank style='color:#2F92EE;'>#PVT1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14915, encryptionId=270014915b3, topicName=PVT1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Wed Sep 03 02:46:00 CST 2014, time=2014-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844149, encodeId=2ef71844149f9, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Fri Oct 24 12:46:00 CST 2014, time=2014-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880140, encodeId=ef75188014016, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jul 05 10:46:00 CST 2014, time=2014-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743418, encodeId=e03b1e434180f, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Sat Mar 07 21:46:00 CST 2015, time=2015-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288137, encodeId=bee4128813e49, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sun Jun 29 04:46:00 CST 2014, time=2014-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517343, encodeId=a3c5151e3437a, content=<a href='/topic/show?id=817b64646b3' target=_blank style='color:#2F92EE;'>#治疗新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64646, encryptionId=817b64646b3, topicName=治疗新靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=251911073486, createdName=12498f1em11(暂无昵称), createdTime=Sun Jun 29 04:46:00 CST 2014, time=2014-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584622, encodeId=2016158462221, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sun Jun 29 04:46:00 CST 2014, time=2014-06-29, status=1, ipAttribution=)]
    2014-09-03 achengzhao

    #PVT1#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2054771, encodeId=39792054e7162, content=<a href='/topic/show?id=c81a14914be' target=_blank style='color:#2F92EE;'>#PVT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14914, encryptionId=c81a14914be, topicName=PVT)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/UdV6ialcayj7Qv8RQm1mVfNYPKxjiaolxwglAZpCo6CwjTicOroW2Xb0Kxnc65viaxGpkuqHW7WzzbYgRLw3qooDoA/132, createdBy=04c22500137, createdName=紫砂壶, createdTime=Wed Aug 20 05:46:00 CST 2014, time=2014-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792917, encodeId=3ae31e9291715, content=<a href='/topic/show?id=270014915b3' target=_blank style='color:#2F92EE;'>#PVT1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14915, encryptionId=270014915b3, topicName=PVT1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Wed Sep 03 02:46:00 CST 2014, time=2014-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844149, encodeId=2ef71844149f9, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Fri Oct 24 12:46:00 CST 2014, time=2014-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880140, encodeId=ef75188014016, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jul 05 10:46:00 CST 2014, time=2014-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743418, encodeId=e03b1e434180f, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Sat Mar 07 21:46:00 CST 2015, time=2015-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288137, encodeId=bee4128813e49, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sun Jun 29 04:46:00 CST 2014, time=2014-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517343, encodeId=a3c5151e3437a, content=<a href='/topic/show?id=817b64646b3' target=_blank style='color:#2F92EE;'>#治疗新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64646, encryptionId=817b64646b3, topicName=治疗新靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=251911073486, createdName=12498f1em11(暂无昵称), createdTime=Sun Jun 29 04:46:00 CST 2014, time=2014-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584622, encodeId=2016158462221, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sun Jun 29 04:46:00 CST 2014, time=2014-06-29, status=1, ipAttribution=)]
    2014-10-24 陈吴1234

    #癌症治疗#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2054771, encodeId=39792054e7162, content=<a href='/topic/show?id=c81a14914be' target=_blank style='color:#2F92EE;'>#PVT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14914, encryptionId=c81a14914be, topicName=PVT)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/UdV6ialcayj7Qv8RQm1mVfNYPKxjiaolxwglAZpCo6CwjTicOroW2Xb0Kxnc65viaxGpkuqHW7WzzbYgRLw3qooDoA/132, createdBy=04c22500137, createdName=紫砂壶, createdTime=Wed Aug 20 05:46:00 CST 2014, time=2014-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792917, encodeId=3ae31e9291715, content=<a href='/topic/show?id=270014915b3' target=_blank style='color:#2F92EE;'>#PVT1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14915, encryptionId=270014915b3, topicName=PVT1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Wed Sep 03 02:46:00 CST 2014, time=2014-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844149, encodeId=2ef71844149f9, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Fri Oct 24 12:46:00 CST 2014, time=2014-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880140, encodeId=ef75188014016, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jul 05 10:46:00 CST 2014, time=2014-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743418, encodeId=e03b1e434180f, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Sat Mar 07 21:46:00 CST 2015, time=2015-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288137, encodeId=bee4128813e49, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sun Jun 29 04:46:00 CST 2014, time=2014-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517343, encodeId=a3c5151e3437a, content=<a href='/topic/show?id=817b64646b3' target=_blank style='color:#2F92EE;'>#治疗新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64646, encryptionId=817b64646b3, topicName=治疗新靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=251911073486, createdName=12498f1em11(暂无昵称), createdTime=Sun Jun 29 04:46:00 CST 2014, time=2014-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584622, encodeId=2016158462221, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sun Jun 29 04:46:00 CST 2014, time=2014-06-29, status=1, ipAttribution=)]
    2014-07-05 liye789132251

    #Nat#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2054771, encodeId=39792054e7162, content=<a href='/topic/show?id=c81a14914be' target=_blank style='color:#2F92EE;'>#PVT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14914, encryptionId=c81a14914be, topicName=PVT)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/UdV6ialcayj7Qv8RQm1mVfNYPKxjiaolxwglAZpCo6CwjTicOroW2Xb0Kxnc65viaxGpkuqHW7WzzbYgRLw3qooDoA/132, createdBy=04c22500137, createdName=紫砂壶, createdTime=Wed Aug 20 05:46:00 CST 2014, time=2014-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792917, encodeId=3ae31e9291715, content=<a href='/topic/show?id=270014915b3' target=_blank style='color:#2F92EE;'>#PVT1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14915, encryptionId=270014915b3, topicName=PVT1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Wed Sep 03 02:46:00 CST 2014, time=2014-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844149, encodeId=2ef71844149f9, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Fri Oct 24 12:46:00 CST 2014, time=2014-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880140, encodeId=ef75188014016, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jul 05 10:46:00 CST 2014, time=2014-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743418, encodeId=e03b1e434180f, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Sat Mar 07 21:46:00 CST 2015, time=2015-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288137, encodeId=bee4128813e49, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sun Jun 29 04:46:00 CST 2014, time=2014-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517343, encodeId=a3c5151e3437a, content=<a href='/topic/show?id=817b64646b3' target=_blank style='color:#2F92EE;'>#治疗新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64646, encryptionId=817b64646b3, topicName=治疗新靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=251911073486, createdName=12498f1em11(暂无昵称), createdTime=Sun Jun 29 04:46:00 CST 2014, time=2014-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584622, encodeId=2016158462221, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sun Jun 29 04:46:00 CST 2014, time=2014-06-29, status=1, ipAttribution=)]
    2015-03-07 d830384

    #非编码#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2054771, encodeId=39792054e7162, content=<a href='/topic/show?id=c81a14914be' target=_blank style='color:#2F92EE;'>#PVT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14914, encryptionId=c81a14914be, topicName=PVT)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/UdV6ialcayj7Qv8RQm1mVfNYPKxjiaolxwglAZpCo6CwjTicOroW2Xb0Kxnc65viaxGpkuqHW7WzzbYgRLw3qooDoA/132, createdBy=04c22500137, createdName=紫砂壶, createdTime=Wed Aug 20 05:46:00 CST 2014, time=2014-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792917, encodeId=3ae31e9291715, content=<a href='/topic/show?id=270014915b3' target=_blank style='color:#2F92EE;'>#PVT1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14915, encryptionId=270014915b3, topicName=PVT1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Wed Sep 03 02:46:00 CST 2014, time=2014-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844149, encodeId=2ef71844149f9, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Fri Oct 24 12:46:00 CST 2014, time=2014-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880140, encodeId=ef75188014016, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jul 05 10:46:00 CST 2014, time=2014-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743418, encodeId=e03b1e434180f, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Sat Mar 07 21:46:00 CST 2015, time=2015-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288137, encodeId=bee4128813e49, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sun Jun 29 04:46:00 CST 2014, time=2014-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517343, encodeId=a3c5151e3437a, content=<a href='/topic/show?id=817b64646b3' target=_blank style='color:#2F92EE;'>#治疗新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64646, encryptionId=817b64646b3, topicName=治疗新靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=251911073486, createdName=12498f1em11(暂无昵称), createdTime=Sun Jun 29 04:46:00 CST 2014, time=2014-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584622, encodeId=2016158462221, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sun Jun 29 04:46:00 CST 2014, time=2014-06-29, status=1, ipAttribution=)]
    2014-06-29 lsndxfj

    #新靶点#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2054771, encodeId=39792054e7162, content=<a href='/topic/show?id=c81a14914be' target=_blank style='color:#2F92EE;'>#PVT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14914, encryptionId=c81a14914be, topicName=PVT)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/UdV6ialcayj7Qv8RQm1mVfNYPKxjiaolxwglAZpCo6CwjTicOroW2Xb0Kxnc65viaxGpkuqHW7WzzbYgRLw3qooDoA/132, createdBy=04c22500137, createdName=紫砂壶, createdTime=Wed Aug 20 05:46:00 CST 2014, time=2014-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792917, encodeId=3ae31e9291715, content=<a href='/topic/show?id=270014915b3' target=_blank style='color:#2F92EE;'>#PVT1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14915, encryptionId=270014915b3, topicName=PVT1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Wed Sep 03 02:46:00 CST 2014, time=2014-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844149, encodeId=2ef71844149f9, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Fri Oct 24 12:46:00 CST 2014, time=2014-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880140, encodeId=ef75188014016, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jul 05 10:46:00 CST 2014, time=2014-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743418, encodeId=e03b1e434180f, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Sat Mar 07 21:46:00 CST 2015, time=2015-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288137, encodeId=bee4128813e49, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sun Jun 29 04:46:00 CST 2014, time=2014-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517343, encodeId=a3c5151e3437a, content=<a href='/topic/show?id=817b64646b3' target=_blank style='color:#2F92EE;'>#治疗新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64646, encryptionId=817b64646b3, topicName=治疗新靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=251911073486, createdName=12498f1em11(暂无昵称), createdTime=Sun Jun 29 04:46:00 CST 2014, time=2014-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584622, encodeId=2016158462221, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sun Jun 29 04:46:00 CST 2014, time=2014-06-29, status=1, ipAttribution=)]
    2014-06-29 12498f1em11(暂无昵称)

    #治疗新靶点#

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2054771, encodeId=39792054e7162, content=<a href='/topic/show?id=c81a14914be' target=_blank style='color:#2F92EE;'>#PVT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14914, encryptionId=c81a14914be, topicName=PVT)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/UdV6ialcayj7Qv8RQm1mVfNYPKxjiaolxwglAZpCo6CwjTicOroW2Xb0Kxnc65viaxGpkuqHW7WzzbYgRLw3qooDoA/132, createdBy=04c22500137, createdName=紫砂壶, createdTime=Wed Aug 20 05:46:00 CST 2014, time=2014-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792917, encodeId=3ae31e9291715, content=<a href='/topic/show?id=270014915b3' target=_blank style='color:#2F92EE;'>#PVT1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14915, encryptionId=270014915b3, topicName=PVT1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Wed Sep 03 02:46:00 CST 2014, time=2014-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844149, encodeId=2ef71844149f9, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Fri Oct 24 12:46:00 CST 2014, time=2014-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880140, encodeId=ef75188014016, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jul 05 10:46:00 CST 2014, time=2014-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743418, encodeId=e03b1e434180f, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Sat Mar 07 21:46:00 CST 2015, time=2015-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288137, encodeId=bee4128813e49, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sun Jun 29 04:46:00 CST 2014, time=2014-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517343, encodeId=a3c5151e3437a, content=<a href='/topic/show?id=817b64646b3' target=_blank style='color:#2F92EE;'>#治疗新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64646, encryptionId=817b64646b3, topicName=治疗新靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=251911073486, createdName=12498f1em11(暂无昵称), createdTime=Sun Jun 29 04:46:00 CST 2014, time=2014-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584622, encodeId=2016158462221, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sun Jun 29 04:46:00 CST 2014, time=2014-06-29, status=1, ipAttribution=)]
    2014-06-29 爆笑小医

    #编码#

    0